$60MSeries B, 25 February 2026
Series B to move lead type 1 diabetes candidate BRZ-101 toward IND.
- Amount
- $60M
- Stage
- Series B
- Announced
- 25 February 2026
- Lead
- Yuanta Investment
- Other investors
- DSC Investment, SV Investment, Kiwoom Investment, Dayli Partners
- Use of funds
- Series B to move lead type 1 diabetes candidate BRZ-101 toward IND.
- Checked
- Announced by the company
- Sources
- BreezeBio (formerly GenEdit) announces $60M Series B vcaonline.com
BreezeBio (formerly GenEdit) announces $60M Series B businesswire.com